Mold-Tek Packaging Q2FY26 Results: Pharma Surge and Margin Expansion Boost Profitability
Mold-Tek Packaging Ltd, a leading manufacturer of rigid plastic packaging, reported a strong performance in Q2FY26 with healthy growth across revenue, profitability, and margins. The company’s performance was supported by robust demand from the pharmaceutical and FMCG segments, along with its continued focus on cost optimization and product innovation.
Despite macroeconomic challenges and higher input costs, Mold-Tek Packaging demonstrated operational resilience and sustained growth momentum. The company’s focus on automation, in-house mold design, and value-added product mix continues to enhance its profitability trajectory.
Financial Highlights — Q2FY26
| Metric | Q2FY26 | YoY / QoQ Change |
|---|---|---|
| Revenue from Operations | ₹240.6 Cr | ↑ 16% YoY |
| Net Profit | ₹15.5 Cr | ↑ from ₹14.1 Cr YoY |
| EBITDA | ₹39.1 Cr | ↑ from ₹33.6 Cr YoY |
| EBITDA Margin | 18.65% | ↑ from 17.55% YoY |
| Profit Before Tax | ₹29.2 Cr | ↑ from ₹25.3 Cr YoY |
| Earnings Per Share (EPS) | ₹6.74 | ↑ from ₹5.25 YoY |
The company’s EBITDA margin improvement was driven by a better product mix, higher pharma contribution, and cost efficiency measures.
For investors tracking packaging and specialty manufacturing companies, check today’s quick market picks:
👉 BankNifty Intraday Tip | F&O Tip
Operational Highlights and Segment Performance
- Pharma Segment: Sales rose 45% QoQ, emerging as a key growth driver in Q2FY26.
- H1FY26 Revenue: ₹450.3 Cr, up 16.05% YoY.
- H1FY26 EBITDA: ₹78.3 Cr, up 22.72% YoY, supported by improved operating leverage.
- Sales Volume: Increased 11.01% YoY in H1FY26, reflecting strong end-user demand.
- Product Mix: Higher share of premium packaging formats aided margins and revenue quality.
The strong pharma demand coupled with expanding FMCG and paint segment sales continues to ensure business stability and predictable cash flows.
Business Strategy and Outlook
- Continued capacity expansions to cater to growing pharma and FMCG demand.
- Focus on in-mold labeling (IML) and digital decoration to enhance value-added product portfolio.
- Investment in R&D for lightweight and eco-friendly packaging solutions.
- Strengthening presence in the pharmaceutical and food segments through client diversification.
Management remains confident of sustaining double-digit revenue growth supported by premiumization, new product development, and consistent margin expansion.
Peer Comparison — Q2FY26 Snapshot
| Company | Revenue Growth (YoY) | EBITDA Margin (%) | PAT Growth (YoY) |
|---|---|---|---|
| Mold-Tek Packaging | 16% | 18.6 | 10% |
| Time Technoplast | 9% | 13.4 | 6% |
| Hitech Plast | 11% | 15.2 | 8% |
Mold-Tek continues to outperform peers in margins and profitability owing to higher efficiency and leadership in value-added packaging solutions.
Investor Takeaway
Indian-Share-Tips.com Nifty Expert Gulshan Khera, CFP®, who is also a SEBI Regd Investment Adviser, observes that Mold-Tek Packaging’s consistent growth in pharma and FMCG verticals, along with its focus on innovation and efficiency, make it a strong mid-cap contender. Its expanding value-added product mix enhances earnings visibility and margin sustainability. Discover more expert-led market insights at Indian-Share-Tips.com, which is a SEBI Registered Advisory Services.
Related Queries
- How did pharma demand boost Mold-Tek’s Q2FY26 results?
- What drives Mold-Tek Packaging’s margin expansion?
- Is Mold-Tek Packaging maintaining growth leadership in the rigid packaging industry?
SEBI Disclaimer: The information provided in this post is for informational purposes only and should not be construed as investment advice. Readers must perform their own due diligence and consult a registered investment advisor before making any investment decisions. The views expressed are general in nature and may not suit individual investment objectives or financial situations.
